These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 17196360)
21. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease. An JY; Choi MG; Noh JH; Sohn TS; Kang WK; Park CK; Kim S Eur J Surg Oncol; 2007 Oct; 33(8):1030-5. PubMed ID: 17428635 [TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate for the treatment of gastrointestinal stromal tumor. Cassier PA; Blay JY Expert Rev Anticancer Ther; 2010 May; 10(5):623-34. PubMed ID: 20469993 [TBL] [Abstract][Full Text] [Related]
23. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774 [TBL] [Abstract][Full Text] [Related]
24. Should surgical resection be combined with imatinib therapy for locally advanced or metastatic gastrointestinal stromal tumors? Yoon SS; Tanabe KK Ann Surg Oncol; 2007 Jun; 14(6):1784-6. PubMed ID: 17356951 [No Abstract] [Full Text] [Related]
25. [Successful treatment of huge peritoneal metastasis from duodenal gastrointestinal stromal tumor resistant for imatinib mesylate]. Sakakura C; Kumano T; Mizuta Y; Yamaoka N; Sagara Y; Hagiwara A; Otsuji E Gan To Kagaku Ryoho; 2007 Nov; 34(12):2144-6. PubMed ID: 18219926 [TBL] [Abstract][Full Text] [Related]
26. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Gronchi A; Fiore M; Miselli F; Lagonigro MS; Coco P; Messina A; Pilotti S; Casali PG Ann Surg; 2007 Mar; 245(3):341-6. PubMed ID: 17435538 [TBL] [Abstract][Full Text] [Related]
27. [Strategy for patients with GIST after failure of imatinib]. Abe S; Kubota T Gan To Kagaku Ryoho; 2009 Apr; 36(4):540-3. PubMed ID: 19381023 [TBL] [Abstract][Full Text] [Related]
28. The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness. Kosmadakis N; Visvardis EE; Kartsaklis P; Tsimara M; Chatziantoniou A; Panopoulos I; Erato P; Capsambelis P Surg Oncol; 2005 Aug; 14(2):75-84. PubMed ID: 15993051 [TBL] [Abstract][Full Text] [Related]
29. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470 [TBL] [Abstract][Full Text] [Related]
30. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor. Zheng S; Pan YL; Tao DY; Wang JL; Huang KE Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980 [TBL] [Abstract][Full Text] [Related]
31. Gastrointestinal stromal tumor with primary resistance to imatinib and extensive bone metastases. Tariq Z; Ghose A; Rafiq E; Mohamed I Am J Ther; 2011 Sep; 18(5):e188-90. PubMed ID: 20535017 [TBL] [Abstract][Full Text] [Related]
32. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors. de Jong FA; Verweij J Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698 [TBL] [Abstract][Full Text] [Related]
33. Current management of GIST. Blanke C Clin Adv Hematol Oncol; 2004 May; 2(5):280, 283. PubMed ID: 17682286 [No Abstract] [Full Text] [Related]
34. Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach. Harrison ML; Goldstein D Intern Med J; 2006 Jun; 36(6):367-77. PubMed ID: 16732863 [TBL] [Abstract][Full Text] [Related]
36. [Surgical treatment of an advanced GIST the age of imatinib]. Fernández JA; Parrilla P Cir Esp; 2009 Jul; 86(1):3-12. PubMed ID: 19539273 [TBL] [Abstract][Full Text] [Related]
37. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK Oncology; 2009; 76(5):326-32. PubMed ID: 19307738 [TBL] [Abstract][Full Text] [Related]
38. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095 [TBL] [Abstract][Full Text] [Related]
39. Gastric GISTs. Personal experience. Mingolla GP; Riccio PA; Linguerri R; La Donna M; Zannelli M; Artuso S Ann Ital Chir; 2007; 78(4):283-8; discussion 288-9. PubMed ID: 17990602 [TBL] [Abstract][Full Text] [Related]
40. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]